Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study DOI Creative Commons

Alex Bakenga,

Barbra Natukunda,

Fred Okuku

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 14, 2024

Prostate cancer is the second most common among men worldwide. Mortality highest patients in resource-limited settings (RLS), part due to late-stage disease. Among with metastatic prostate (mPCa), studies have shown significant improvement overall survival use of androgen deprivation therapy (ADT) and taxane-based chemotherapy. However, outcome data treated chemo-endocrine are scarce many settings. The aim this study was determine clinical characteristics 5-year (OS) de novo mPCa at Uganda Cancer Institute (UCI). A retrospective chart review conducted between 2015 2019, histologically confirmed radiological evidence metastasis were reviewed. Sample size estimated for Cox Proportion Hazard regression. Data on laboratory characteristics, survival, predictors extracted. P < 0.05 considered indicate statistical significance. total 300 enrolled over period. median age 68 (IQR 61.5–74) years. At presentation, lower urinary tract symptoms reported nearly all (96.7%, n = 290), specific antigen (PSA) 414.75 ng/ml 40% (n 120) had grade 5 histological scores. In addition receiving ADT, majority (70.3%, 211) received least 6 cycles Overall one year 92.4% (95% CI: 88.6-94.9%), but it declined 45.2% 36.8-53.2%) high Gleason score, presence visceral less than chemotherapy poor outcomes. Patients present histologic grades baseline Specific Antigen levels improved a combination ADT as first-line treatment. We recommend interventions reduce late presentation prospective evaluate treatment efficacy population.

Language: Английский

Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study DOI Creative Commons

Alex Bakenga,

Barbra Natukunda,

Fred Okuku

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 14, 2024

Prostate cancer is the second most common among men worldwide. Mortality highest patients in resource-limited settings (RLS), part due to late-stage disease. Among with metastatic prostate (mPCa), studies have shown significant improvement overall survival use of androgen deprivation therapy (ADT) and taxane-based chemotherapy. However, outcome data treated chemo-endocrine are scarce many settings. The aim this study was determine clinical characteristics 5-year (OS) de novo mPCa at Uganda Cancer Institute (UCI). A retrospective chart review conducted between 2015 2019, histologically confirmed radiological evidence metastasis were reviewed. Sample size estimated for Cox Proportion Hazard regression. Data on laboratory characteristics, survival, predictors extracted. P < 0.05 considered indicate statistical significance. total 300 enrolled over period. median age 68 (IQR 61.5–74) years. At presentation, lower urinary tract symptoms reported nearly all (96.7%, n = 290), specific antigen (PSA) 414.75 ng/ml 40% (n 120) had grade 5 histological scores. In addition receiving ADT, majority (70.3%, 211) received least 6 cycles Overall one year 92.4% (95% CI: 88.6-94.9%), but it declined 45.2% 36.8-53.2%) high Gleason score, presence visceral less than chemotherapy poor outcomes. Patients present histologic grades baseline Specific Antigen levels improved a combination ADT as first-line treatment. We recommend interventions reduce late presentation prospective evaluate treatment efficacy population.

Language: Английский

Citations

0